OncoMatch/Clinical Trials/NCT06970145
Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
Is NCT06970145 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Anlotinib for craniopharyngiomas.
Treatment: Anlotinib — Primary Aim: To assess the objective remission rate (ORR) of patients with recurrent craniopharyngiomas treated with anlotinib . Secondary Aims: 1. To assess progression-free survival (PFS) and overall survival (OS) of patients with recurrent craniopharyngiomas treated with anlotinib. 2. To analyze the disease control rate (DCR) of the anlotinib treatment regimen in patients with recurrent craniopharyngiomas, including the proportion of patients in complete remission, partial remission and stable disease. 3. Monitor and evaluate the safety of anlotinib, especially the occurrence of drug-related adverse events (AEs) .
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Demographics
Prior therapy
Must have received: surgery
recurrence after total resection or regrowth of residual tumor
Cannot have received: same investigational drug
prior treatment with the same investigational drug
Lab requirements
Blood counts
blood tests within the normal range or under control
Kidney function
kidney function within the normal range or under control
Liver function
liver function within the normal range or under control
laboratory parameters (liver and kidney function, blood tests, etc.) within the normal range or under control
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06970145 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior same investigational drug disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify